FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2103152130> ?p ?o ?g. }

• W2103152130 endingPage "3190" @default.
• W2103152130 startingPage "3182" @default.
• W2103152130 abstract "Purpose Amplifications and mutations in the KIT proto-oncogene in subsets of melanomas provide therapeutic opportunities. Patients and Methods We conducted a multicenter phase II trial of imatinib in metastatic mucosal, acral, or chronically sun-damaged (CSD) melanoma with KIT amplifications and/or mutations. Patients received imatinib 400 mg once per day or 400 mg twice per day if there was no initial response. Dose reductions were permitted for treatment-related toxicities. Additional oncogene mutation screening was performed by mass spectroscopy. Results Twenty-five patients were enrolled (24 evaluable). Eight patients (33%) had tumors with KIT mutations, 11 (46%) with KIT amplifications, and five (21%) with both. Median follow-up was 10.6 months (range, 3.7 to 27.1 months). Best overall response rate (BORR) was 29% (21% excluding nonconfirmed responses) with a two-stage 95% CI of 13% to 51%. BORR was significantly greater than the hypothesized null of 5% and statistically significantly different by mutation status (7 of 13 or 54% KIT mutated v 0% KIT amplified only). There were no statistical differences in rates of progression or survival by mutation status or by melanoma site. The overall disease control rate was 50% but varied significantly by KIT mutation status (77% mutated v 18% amplified). Four patients harbored pretreatment NRAS mutations, and one patient acquired increased KIT amplification after treatment. Conclusion Melanomas that arise on mucosal, acral, or CSD skin should be assessed for KIT mutations. Imatinib can be effective when tumors harbor KIT mutations, but not if KIT is amplified only. NRAS mutations and KIT copy number gain may be mechanisms of therapeutic resistance to imatinib." @default.
• W2103152130 created "2016-06-24" @default.
• W2103152130 creator A5001015275 @default.
• W2103152130 creator A5002655892 @default.
• W2103152130 creator A5015498468 @default.
• W2103152130 creator A5023174631 @default.
• W2103152130 creator A5024343002 @default.
• W2103152130 creator A5026593581 @default.
• W2103152130 creator A5027911766 @default.
• W2103152130 creator A5035089484 @default.
• W2103152130 creator A5040359760 @default.
• W2103152130 creator A5042555322 @default.
• W2103152130 creator A5047177507 @default.
• W2103152130 creator A5049104586 @default.
• W2103152130 creator A5049839632 @default.
• W2103152130 creator A5060495866 @default.
• W2103152130 creator A5060580923 @default.
• W2103152130 creator A5061310592 @default.
• W2103152130 creator A5063337705 @default.
• W2103152130 creator A5071788399 @default.
• W2103152130 creator A5077388635 @default.
• W2103152130 creator A5078874539 @default.
• W2103152130 creator A5084967339 @default.
• W2103152130 creator A5085317448 @default.
• W2103152130 creator A5089516753 @default.
• W2103152130 creator A5091057405 @default.
• W2103152130 date "2013-09-10" @default.
• W2103152130 modified "2023-10-17" @default.
• W2103152130 title "Imatinib for Melanomas Harboring Mutationally Activated or Amplified <i>KIT</i> Arising on Mucosal, Acral, and Chronically Sun-Damaged Skin" @default.
• W2103152130 cites W1655448040 @default.
• W2103152130 cites W1913085465 @default.
• W2103152130 cites W1967570424 @default.
• W2103152130 cites W1989121777 @default.
• W2103152130 cites W1994376203 @default.
• W2103152130 cites W1999106017 @default.
• W2103152130 cites W2015015957 @default.
• W2103152130 cites W2015682571 @default.
• W2103152130 cites W2018789635 @default.
• W2103152130 cites W2019496774 @default.
• W2103152130 cites W2019950585 @default.
• W2103152130 cites W2053473615 @default.
• W2103152130 cites W2053520756 @default.
• W2103152130 cites W2064286154 @default.
• W2103152130 cites W2079641245 @default.
• W2103152130 cites W2091124293 @default.
• W2103152130 cites W2096223992 @default.
• W2103152130 cites W2099200814 @default.
• W2103152130 cites W2103549763 @default.
• W2103152130 cites W2118583448 @default.
• W2103152130 cites W2121637902 @default.
• W2103152130 cites W2122376569 @default.
• W2103152130 cites W2147474070 @default.
• W2103152130 cites W2150501295 @default.
• W2103152130 cites W2156266404 @default.
• W2103152130 cites W2163188200 @default.
• W2103152130 cites W2168029948 @default.
• W2103152130 cites W4254073564 @default.
• W2103152130 doi "https://doi.org/10.1200/jco.2012.47.7836" @default.
• W2103152130 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4878082" @default.
• W2103152130 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23775962" @default.
• W2103152130 hasPublicationYear "2013" @default.
• W2103152130 type Work @default.
• W2103152130 sameAs 2103152130 @default.
• W2103152130 citedByCount "477" @default.
• W2103152130 countsByYear W21031521302013 @default.
• W2103152130 countsByYear W21031521302014 @default.
• W2103152130 countsByYear W21031521302015 @default.
• W2103152130 countsByYear W21031521302016 @default.
• W2103152130 countsByYear W21031521302017 @default.
• W2103152130 countsByYear W21031521302018 @default.
• W2103152130 countsByYear W21031521302019 @default.
• W2103152130 countsByYear W21031521302020 @default.
• W2103152130 countsByYear W21031521302021 @default.
• W2103152130 countsByYear W21031521302022 @default.
• W2103152130 countsByYear W21031521302023 @default.
• W2103152130 crossrefType "journal-article" @default.
• W2103152130 hasAuthorship W2103152130A5001015275 @default.
• W2103152130 hasAuthorship W2103152130A5002655892 @default.
• W2103152130 hasAuthorship W2103152130A5015498468 @default.
• W2103152130 hasAuthorship W2103152130A5023174631 @default.
• W2103152130 hasAuthorship W2103152130A5024343002 @default.
• W2103152130 hasAuthorship W2103152130A5026593581 @default.
• W2103152130 hasAuthorship W2103152130A5027911766 @default.
• W2103152130 hasAuthorship W2103152130A5035089484 @default.
• W2103152130 hasAuthorship W2103152130A5040359760 @default.
• W2103152130 hasAuthorship W2103152130A5042555322 @default.
• W2103152130 hasAuthorship W2103152130A5047177507 @default.
• W2103152130 hasAuthorship W2103152130A5049104586 @default.
• W2103152130 hasAuthorship W2103152130A5049839632 @default.
• W2103152130 hasAuthorship W2103152130A5060495866 @default.
• W2103152130 hasAuthorship W2103152130A5060580923 @default.
• W2103152130 hasAuthorship W2103152130A5061310592 @default.
• W2103152130 hasAuthorship W2103152130A5063337705 @default.
• W2103152130 hasAuthorship W2103152130A5071788399 @default.
• W2103152130 hasAuthorship W2103152130A5077388635 @default.
• W2103152130 hasAuthorship W2103152130A5078874539 @default.
• W2103152130 hasAuthorship W2103152130A5084967339 @default.
• W2103152130 hasAuthorship W2103152130A5085317448 @default.

• next